Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
If the ceiling of the total drug costs can be controlled, will Japanese financial authorities tolerate increases in pharmaceutical spending? A health ministry expert panel on October 27 saw a verbal skirmish among former bureaucrats and academics over the concept…
To read the full story
Related Article
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
REGULATORY
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…